[go: up one dir, main page]

BRPI0606110A2 - compostos de arilamina substituìdos e seu uso como 5 - ht6 moduladores - Google Patents

compostos de arilamina substituìdos e seu uso como 5 - ht6 moduladores

Info

Publication number
BRPI0606110A2
BRPI0606110A2 BRPI0606110-9A BRPI0606110A BRPI0606110A2 BR PI0606110 A2 BRPI0606110 A2 BR PI0606110A2 BR PI0606110 A BRPI0606110 A BR PI0606110A BR PI0606110 A2 BRPI0606110 A2 BR PI0606110A2
Authority
BR
Brazil
Prior art keywords
substituted
alkyl
heteroaryl
aryl
hydrogen
Prior art date
Application number
BRPI0606110-9A
Other languages
English (en)
Inventor
Oren Becker
Srinivasa Rao Cheruku
Yael Marantz
Silvia Noiman
Merav Fichman
Hanoch Senderowitz
Sharon Shacham
Ashis Saha
Pini Orbach
Mercedes Lobera
Rosa E Melendez
Anurag Sharadendu
Laurence Wu
Xiang Y Yu
Dale S Dhanoa
Original Assignee
Epix Delaware Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epix Delaware Inc filed Critical Epix Delaware Inc
Publication of BRPI0606110A2 publication Critical patent/BRPI0606110A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPOSTOS DE ARILAMINA SUBSTITUìDOS E SEU USO COMO 5-HT6 MODULADORES. A invenção refere-se a antagonistas de 5-HT6 receptores. São descritos novos compostos de arilamina tendo a fórmula: e sais e/ou ésteres dos mesmos farmaçeuticamente aceitáveis, em que - n é 0,1, 2, 3, ou 4; - A, quando presente é um grupo alquila inferior; - R~ 1~ é hidrogênio ou alquila ou arila substituído ou não-substituído; - R~ 2~ é hidrogênio; halo; nitro; ciano; alçóxi inferior; ácido de sal de carboxilato ou éster de aíquila do mesmo; uma sulfona; haloalquila ou haloalcóxi; acetaldeido; carboxamida; carbomila; alcoxiaminocarbonila; ou arilalquilamino substituído; - R~ 3 e R~ 4~ são de modo independente hidrogênio, substituído ou não-substituído alquila, arila, alquilarila, heteroarila ou alquilheteroarila, ou, tomados juntos, R~ 3~ e R~ 4~ formam um grupo substituido ou não-substituído arila; alquilarila, heteroarila ou alquilheteroarila; - B, quando presente, é alquila inferior; e - X e Y são de modo independente O ou N; e o uso destes compostos e suas composições farmacêuticas, por exemplo, no tratamento, modulação e/ou prevenção de condições fisiológicas associadas com a ação da serotonina, tais como no tratamento da obesidade, e de distúrbios relacionados com obesidade, por exemplo, doença cardiovascular, doença digestiva, doença respiratória, câncer e diabetes tipo II; e distúrbios psicológicos tais como esquizofrenia.
BRPI0606110-9A 2005-01-25 2006-01-25 compostos de arilamina substituìdos e seu uso como 5 - ht6 moduladores BRPI0606110A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64695705P 2005-01-25 2005-01-25
US70185305P 2005-07-22 2005-07-22
PCT/US2006/002718 WO2006081332A1 (en) 2005-01-25 2006-01-25 Substituted arylamine compounds and their use as 5-ht6 modulators

Publications (1)

Publication Number Publication Date
BRPI0606110A2 true BRPI0606110A2 (pt) 2009-06-02

Family

ID=36406535

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606110-9A BRPI0606110A2 (pt) 2005-01-25 2006-01-25 compostos de arilamina substituìdos e seu uso como 5 - ht6 moduladores

Country Status (14)

Country Link
US (2) US7968538B2 (pt)
EP (1) EP1856075A1 (pt)
JP (2) JP5186219B2 (pt)
KR (1) KR20070097590A (pt)
AU (1) AU2006209216A1 (pt)
BR (1) BRPI0606110A2 (pt)
CA (1) CA2595607C (pt)
IL (1) IL184705A0 (pt)
MA (1) MA29429B1 (pt)
MX (1) MX2007008279A (pt)
NO (1) NO20074324L (pt)
NZ (1) NZ556761A (pt)
RU (1) RU2440996C2 (pt)
WO (1) WO2006081332A1 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7482337B2 (en) * 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7153858B2 (en) * 2003-01-31 2006-12-26 Epix Delaware, Inc. Arylpiperazinyl compounds
US20050222175A1 (en) * 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7612078B2 (en) * 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
DE102004009039A1 (de) * 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US7488736B2 (en) * 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
DE102004030502A1 (de) * 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
US7598265B2 (en) * 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
US7576211B2 (en) * 2004-09-30 2009-08-18 Epix Delaware, Inc. Synthesis of thienopyridinone compounds and related intermediates
US7407966B2 (en) * 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
EP1676842A1 (en) * 2004-12-30 2006-07-05 Laboratorios Del Dr. Esteve, S.A. Nitro-substituted phenyl-piperazine compounds, their preparation and use in medicaments
MX2007008279A (es) 2005-01-25 2008-02-15 Epix Delaware Inc Compuestos de arilamina sustituidos y su uso como moduladores de la 5-ht6.
AR061637A1 (es) * 2006-06-26 2008-09-10 Epix Delaware Inc Composiciones y metodos de tratamiento de trastornos del snc
NZ577114A (en) 2006-12-19 2011-12-22 Hoffmann La Roche Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives
MX2009010242A (es) 2007-03-23 2009-12-14 Abbott Gmbh & Co Kg Compuestos de azetidina adecuados para el tratamiento de trastornos que responden a la modulacion del receptor de serotonina 5-ht6.
EP2103596A1 (en) * 2008-03-18 2009-09-23 Laboratorios Del. Dr. Esteve, S.A. Process for the preparation of N-(phenylethyl) anilines salts and solvates thereof useful as serotonin 5-HT6 antagonists
ES2353297B1 (es) * 2008-03-18 2011-09-26 Laboratorios Del Dr. Esteve, S. A. Procedimiento para la preparación de n-(1-feniletil)anilinas, sales, y solvatos de las mismas útiles como antagonistas de 5-ht6 de serotonina.
WO2010065743A2 (en) * 2008-12-03 2010-06-10 Nanotherapeutics, Inc. Bicyclic compounds and methods of making and using same
US8916584B2 (en) * 2010-02-11 2014-12-23 Vanderbilt University Benzisoxazoles and azabenzisoxazoles as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
TWI458145B (zh) 2011-12-20 2014-10-21 Ind Tech Res Inst 超導材料的接合方法
IL246002B2 (en) * 2013-12-03 2024-11-01 Intra Cellular Therapies Inc Converted compounds of gamma-carboline fused with heterocycles for use in the treatment of residual symptoms of psychosis and a long-acting injectable preparation containing these compounds in a matrix
WO2018071233A1 (en) 2016-10-12 2018-04-19 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
EP3548034A4 (en) * 2016-12-05 2020-07-08 Microbiotix, Inc. BROAD SPECTRUM INHIBITORS OF FILOVIRUS
IL304026B2 (en) 2017-03-24 2024-11-01 Intra Cellular Therapies Inc A pharmaceutical preparation containing 1-(4-fluoro-phenyl)-4-((Sa10,Rb6)-3-D2-2,2-methyl-2, 3, a10, 10, 9, b6- hexahydro-H7, H1- Pyrido[3',4',:4,5]pyrrolo[3,2,1-de]quioxalin-8-yl)-butan-1-one and its uses
EP4092013A1 (en) 2017-06-20 2022-11-23 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
KR101992621B1 (ko) 2017-12-07 2019-09-27 주식회사 온코빅스 암세포 성장 억제 효과를 나타내는 신규한 피리미딘 유도체 및 그를 포함하는 약제학적 조성물
US12144808B2 (en) 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
MX2021002322A (es) 2018-08-31 2021-04-28 Intra Cellular Therapies Inc Nuevos metodos.
BR112021003838A2 (pt) 2018-08-31 2021-05-18 Intra-Cellular Therapies, Inc. métodos novos
EP4497474A3 (en) 2018-10-17 2025-04-23 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds
MX2022000143A (es) 2019-07-07 2022-02-17 Intra Cellular Therapies Inc Metodos novedosos.
CN112574201B (zh) * 2019-09-29 2024-04-19 四川科伦博泰生物医药股份有限公司 芳基胺类化合物、包含其的药物组合物及其制备方法和用途
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
MX2023005971A (es) 2020-11-20 2023-06-07 2692372 Ontario Inc Metodos y composicion para las modificaciones de kras.
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1211359B (de) * 1955-11-29 1966-02-24 Oreal Oxydationsmittelfreies Kaltfaerbemittel fuer menschliches Haar
JPH0413669A (ja) 1990-04-27 1992-01-17 Mitsui Toatsu Chem Inc 新規ピリミジンジオン誘導体及び該化合物を含有する抗不整脈剤
DE4238994A1 (de) 1992-11-19 1994-05-26 Basf Ag Aniline als Markierungsmittel für Mineralöle
JPH07300474A (ja) * 1994-05-02 1995-11-14 Asahi Chem Ind Co Ltd テトラハイドロキノキサリン誘導体およびその用途
FR2722788B1 (fr) * 1994-07-20 1996-10-04 Pf Medicament Nouvelles piperazides derivees d'aryl piperazine, leurs procedes de preparation, leur utilisation a titre de medicament et les compositions pharmaceutiques les comprenant
US5888941A (en) 1995-08-02 1999-03-30 J. Uriach & Cia. S.A. Carbozamides with antifungal activity
FR2740134B1 (fr) * 1995-10-18 1998-01-09 Pf Medicament Derives d'amines cycliques d'aryl-piperazines, leur preparation et les compositions pharmaceutiques les contenant
US6391871B1 (en) 1996-09-20 2002-05-21 John W. Olney Preventing neuronal degeneration in Alzheimer's disease
US20010051719A1 (en) 1996-12-19 2001-12-13 Smithkline Beecham P.L.C. Novel compounds
JP4095676B2 (ja) 1997-03-03 2008-06-04 エーザイ株式会社 注意障害を治療するためのコリンエステラーゼ阻害剤の使用
FR2761064B1 (fr) * 1997-03-20 1999-06-04 Pf Medicament Piperazines derivees d'amines cycliques, leur preparation et leur application comme medicaments
SK285198B6 (sk) * 1997-10-27 2006-08-03 Neurosearch A/S Homopiperazínový derivát, farmaceutická kompozícia obsahujúca tento derivát a jeho použitie
DE69839735D1 (de) * 1997-12-15 2008-08-28 Astellas Pharma Inc Pyrimidin-5-carboxamid-derivate
IT1304904B1 (it) 1998-09-11 2001-04-05 Eisai Co Ltd Derivati anticolinesterasici per il trattamento delle sindromidolorose funzionali e/o organiche
CZ20012444A3 (cs) 1999-01-07 2002-02-13 American Home Products Corporation Arylpiperazinylcyklohexylindolové deriváty pro léčbu deprese
US6972287B1 (en) 1999-06-10 2005-12-06 Pfizer Inc. Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
CN1167686C (zh) * 1999-06-22 2004-09-22 神经研究公司 苯并咪唑衍生物和包括这些化合物的药物组合物
US6610713B2 (en) 2000-05-23 2003-08-26 North Shore - Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
PE20020063A1 (es) * 2000-06-20 2002-01-30 Upjohn Co Bis-arilsulfonas como ligandos del receptor de 5-ht
US20040122090A1 (en) 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
EP1372620A2 (en) 2001-03-15 2004-01-02 Saegis Pharmaceuticals Methods for restoring cognitive function following systemic stress
US20030095958A1 (en) * 2001-04-27 2003-05-22 Bhisetti Govinda R. Inhibitors of bace
BR0209558A (pt) 2001-05-11 2004-04-20 Biovitrum Ab Novos compostos de arilsulfonamida para o tratamento de obesidade, diabetes tipo ii e distúrbios do snc
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
US6638981B2 (en) 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
CN101851173A (zh) * 2001-09-14 2010-10-06 梅特希尔基因公司 组蛋白脱乙酰化酶抑制剂
WO2003080060A1 (en) * 2002-03-20 2003-10-02 Schering Aktiengesellschaft Substituted piperazine antithrombotic pai-1 inhibitors
WO2004034963A2 (en) 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
TW200403243A (en) 2002-07-18 2004-03-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands
JP2006514989A (ja) 2002-07-29 2006-05-18 ライジェル ファーマシューティカルズ ２，４−ピリミジンジアミン化合物による自己免疫疾患の治療および予防方法
EP1590329A1 (fr) 2003-01-28 2005-11-02 Aventis Pharma S.A. Produits n-aryl-heteroaromatiques, compositions les contenant et utilisation
US7153858B2 (en) 2003-01-31 2006-12-26 Epix Delaware, Inc. Arylpiperazinyl compounds
AR043467A1 (es) 2003-03-05 2005-07-27 Osmotica Argentina S A Combinacion de drogas para la disfuncion motora en la enfermedad de parkinson
GB0305929D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US20050222175A1 (en) 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7612078B2 (en) 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7030240B2 (en) 2003-03-31 2006-04-18 Predix Pharmaceuticals Holdings, Inc. Piperidinylamino-thieno[2,3-d] pyrimidine compounds
WO2005000217A2 (en) 2003-06-06 2005-01-06 Merck & Co., Inc. Combination therapy for the treatment of dyslipidemia
AU2003261255A1 (en) 2003-07-24 2005-03-07 Cargill, Incorporated A food composition contain lecithin
ES2222827B1 (es) 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
GB0321710D0 (en) * 2003-09-16 2003-10-15 Novartis Ag Organic compounds
US20050143350A1 (en) 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
AU2005215775B2 (en) 2004-02-13 2011-02-03 Neuromolecular, Inc. Combination of a NMDA receptor antagonist and an anti-depressive drug MAO-inhibitor or a GADPH-inhibitor for the treatment of psychiatric conditions
US7488736B2 (en) 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
GB0411791D0 (en) 2004-05-26 2004-06-30 Cyclacel Ltd Compounds
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
US7407966B2 (en) 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7576211B2 (en) 2004-09-30 2009-08-18 Epix Delaware, Inc. Synthesis of thienopyridinone compounds and related intermediates
US7598265B2 (en) 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
US20060240043A1 (en) 2004-10-08 2006-10-26 Meyerson Laurence R Methods and compositions for treating migraine pain
EP1828185B1 (en) * 2004-12-21 2009-05-06 SmithKline Beecham Corporation 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
BRPI0519424B8 (pt) 2004-12-28 2021-05-25 Athenex Inc compostos, composição e uso dos ditos compostos para a preparação de um medicamento para prevenção ou tratamento de um distúrbio de proliferação celular ou infecção microbiana
EP1695971A1 (en) * 2004-12-30 2006-08-30 Laboratorios Del Dr. Esteve, S.A. Substituted phenyl-piperazine compounds, their preparation and use in medicaments
EP1676842A1 (en) * 2004-12-30 2006-07-05 Laboratorios Del Dr. Esteve, S.A. Nitro-substituted phenyl-piperazine compounds, their preparation and use in medicaments
MX2007008279A (es) 2005-01-25 2008-02-15 Epix Delaware Inc Compuestos de arilamina sustituidos y su uso como moduladores de la 5-ht6.
CA2597566A1 (en) 2005-02-11 2006-08-17 Stephen Wills Treating microvasculature diseases with acetyl cholinesterase inhibitors
US20060194723A1 (en) 2005-02-28 2006-08-31 Rabinoff Michael D Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement
PL2982372T3 (pl) 2005-04-05 2020-12-28 Yale University Środki modulujące stężenie glutaminianu stosowane w leczeniu zaburzeń psychicznych
US20060270650A1 (en) 2005-05-26 2006-11-30 Macneil Tanya Combination therapy for the treatment of obesity
US7919519B2 (en) 2005-11-23 2011-04-05 Epix Pharmaceuticals Inc. S1P receptor modulating compounds and use thereof
JP2009520688A (ja) 2005-11-23 2009-05-28 エピックス デラウェア， インコーポレイテッド Ｓ１ｐ受容体調節化合物およびそれらの使用
EP2010524A2 (en) 2006-03-21 2009-01-07 Epix Delaware, Inc. S1p receptor modulating compounds

Also Published As

Publication number Publication date
WO2006081332A1 (en) 2006-08-03
US20120115850A1 (en) 2012-05-10
MA29429B1 (fr) 2008-05-02
US8604021B2 (en) 2013-12-10
RU2007132161A (ru) 2009-03-10
US20060205737A1 (en) 2006-09-14
MX2007008279A (es) 2008-02-15
KR20070097590A (ko) 2007-10-04
JP2012111784A (ja) 2012-06-14
EP1856075A1 (en) 2007-11-21
CA2595607A1 (en) 2006-08-03
NZ556761A (en) 2011-04-29
NO20074324L (no) 2007-10-25
RU2440996C2 (ru) 2012-01-27
JP2008528517A (ja) 2008-07-31
AU2006209216A1 (en) 2006-08-03
CA2595607C (en) 2014-07-15
JP5186219B2 (ja) 2013-04-17
IL184705A0 (en) 2007-12-03
US7968538B2 (en) 2011-06-28

Similar Documents

Publication Publication Date Title
BRPI0606110A2 (pt) compostos de arilamina substituìdos e seu uso como 5 - ht6 moduladores
AU2019219123B2 (en) Non-fused thiophene derivatives and their uses
AR070487A1 (es) Derivados de 3- metil- imidazo -( 1,2-b)- piridazina
EA201170705A1 (ru) Арилметилбензохиназолиноны в качестве позитивных аллостерических модуляторов рецептора м1
BRPI0013667B8 (pt) derivados de glucopiranosiloxipirazol, composições medicinais contendo os mesmos e seus intermediários na produção deles
ATE517882T1 (de) Chinolinderivate
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
NO20090979L (no) (3-amino-1,2,3,4-tetrahydro-9H-karbazol-9-yl)-eddiksyrederivater
RU2006105717A (ru) Производные пиперазина и их применение в качестве терапевтических агентов
AR036596A1 (es) Derivados de 4,5-dihidro-1h-pirazol que tienen actividad antagonista de cb1
UA102517C2 (ru) Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы
IL189191A0 (en) Thiazolyl piperidine derivatives useful as h3 receptor modulators
AR077935A1 (es) Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina
BRPI0407283A (pt) Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade
BRPI0821266B8 (pt) Derivados de arilamida triazol-substituída e seu uso e composição farmacêutica
RU2008152180A (ru) ПРОИЗВОДНЫЕ ПИРРОЛА, МОДУЛИРУЮЩИЕ АКТИВНОСТЬ CRTh2 РЕЦЕПТОРА
BRPI0417208A (pt) derivados de 8'-piri(mi)dinil-diidroespiro-[cicloalquilamina]-pirimid o[1,2-ona]pirimidin-6-ona
UA95766C2 (ru) Производные терфенила для лечения болезни альцгеймера
AR040246A1 (es) Derivados de 1-piperazinilacilpiperidina substituidos, su preparacion y su aplicacion en terapeutica
CA2828831C (en) Compounds and methods for the treatment of pain and other disorders
ATE512142T1 (de) Pyrimidin- und chinazolinderivate als modulatoren der somatostatin-rezeptor aktivität
DE602007013040D1 (de) 4-Ä(3-FLUORPHENOXY)PHENYLMETHYLÜPIPERIDINMETHANiSULFONAT: VERWENDUNGEN, SYNTHESEVERFAHREN UND PHARMAZEUTISCHE ZUSAMMENSETZUNGEN
WO2008077810A3 (en) Spiro-piperidine derivatives
WO2007080124A1 (en) Combination of mtor inhibitor and antipolate compound
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: GALENEA CORP. (US)

Free format text: TRANSFERIDO DE: EPIX DELAWARE, INC.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2290 DE 25/11/2014.